| Aug 13 |
Eyenovia to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
|
| Aug 13 |
Eyenovia, Inc. (EYEN) Q2 2024 Earnings Call Transcript
|
| Aug 12 |
Eyenovia, Inc. (EYEN) Reports Q2 Loss, Misses Revenue Estimates
|
| Aug 12 |
Eyenovia GAAP EPS of -$0.21 misses by $0.06, revenue of $22.63M
|
| Aug 12 |
Eyenovia Reports Second Quarter 2024 Financial Results and Provides Corporate Update
|
| Aug 8 |
Eyenovia to Report Second Quarter 2024 Results on Monday, August 12th
|
| Aug 7 |
Eyenovia and Formosa Pharmaceuticals Initiate Co-Development of Clobetasol Propionate Ophthalmic Suspension (0.05%) for the Treatment of Acute Dry Eye Disease in the U.S.
|
| Aug 7 |
Formosa Pharma and Eyenovia Announce Initiation of Co-Development of Clobetasol Propionate Ophthalmic Suspension, 0.05%, for the treatment of Acute Dry Eye Disease in United States
|
| Jul 30 |
Eyenovia & SGN Nanopharma collaborate to develop treatment for chronic dry eye disease
|
| Jul 30 |
Eyenovia & SGN Nanopharma Announce Collaboration Agreement to Develop Novel Treatment for Chronic Dry Eye Disease
|
